10185-68-9

Usage

Uses

Used in Pharmaceutical and Agrochemical Synthesis:
4-(5-METHYL-1,2,4-OXADIAZOL-3-YL)ANILINE is used as a building block for the synthesis of pharmaceuticals and agrochemicals due to its potential for biological activity. Its unique structure allows for the development of new compounds with therapeutic or pesticidal properties.
Used in Organic Electronic Materials:
In the field of organic electronics, 4-(5-METHYL-1,2,4-OXADIAZOL-3-YL)ANILINE is used as a component in the development of materials with specific electronic properties. Its incorporation can enhance the performance of organic electronic devices, such as organic light-emitting diodes (OLEDs) and organic solar cells.
Used as a Fluorescent Probe in Biological Imaging:
4-(5-METHYL-1,2,4-OXADIAZOL-3-YL)ANILINE is utilized as a fluorescent probe in biological imaging. Its fluorescent properties allow researchers to track and visualize biological processes at the molecular level, contributing to advancements in life sciences research.
Used in Antimicrobial and Antiviral Applications:
4-(5-METHYL-1,2,4-OXADIAZOL-3-YL)ANILINE has been reported to exhibit antimicrobial and antiviral properties in certain studies. It is used as an active ingredient in the development of new antimicrobial and antiviral agents, potentially offering novel therapeutic solutions for infectious diseases.

InChI:InChI=1/C9H9N3O/c1-6-11-9(12-13-6)7-2-4-8(10)5-3-7/h2-5H,10H2,1H3

Upstream product

• 277319-62-7 4-amino-N'-hydroxybenzimidamide 
• 141-78-6 ethyl acetate 
• 937-31-5 (4-Nitrophenyl)acetylene 
• 192332-48-2 (Z)-4-nitrobenzamidoxime 
• 619-72-7 4-nitrobenzonitrile 
• 555-16-8 4-nitrobenzaldehdye 
• 25283-96-9 3-(4-methoxyphenyl)-5-methyl-1,2,4-oxadiazole 
• 918967-52-9 tert-butyl (4-(N’-hydroxycarbamimidoyl)phenyl)carbamate 
• 873-74-5 4-Aminobenzonitrile 
• 143090-18-0 tert-butyl N-(4-cyanophenyl)carbamate 
• 643744-95-0 [4-(5-methyl-[1,2,4]oxadiazol-3-yl)-phenyl]-carbamic acid tert-butyl ester 

Downstream Products

• 1160931-81-6 2-(5-((5-(4-chlorophenyl)furan-2-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)-N-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)acetamide 

Relevant academic research and scientific papers

The first one-pot ambient-temperature synthesis of 1,2,4-oxadiazoles from amidoximes and carboxylic acid esters

The first one-pot room-temperature protocol for the synthesis of 3,5-disubstituted-1,2,4-oxadiazoles via the condensation between amidoximes and carboxylic acid esters in superbase medium MOH/DMSO is reported. A broad spectrum of alkyl, aryl and hetaryl amidoximes and esters was examined. This reaction route provides convenient access to 1,2,4-oxadiazoles, which is highly desirable because in the light of this privileged scaffold is recognized as an important core in the design of novel therapeutic agents and high-tech materials.

HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions in need of inhibition of heparan sulfate biosynthesis.

Synthesis and methemoglobinemia-inducing properties of benzocaine isosteres designed as humane rodenticides

A number of isosteres (oxadiazoles, thiadiazoles, tetrazoles and diazines) of benzocaine were prepared and evaluated for their capacity to induce methemoglobinemia - with a view to their possible application as humane pest control agents. It was found that an optimal lipophilicity for the formation of methemoglobin (metHb) in vitro existed within each series, with 1,2,4-oxadiazole 3 (metHb% = 61.0 ± 3.6) and 1,3,4-oxadiazole 10 (metHb% = 52.4 ± 0.9) demonstrating the greatest activity. Of the 5 candidates (compounds 3, 10, 11, 13 and 23) evaluated in vivo, failure to induce a lethal end-point at doses of 120 mg/kg was observed in all cases. Inadequate metabolic stability, particularly towards hepatic enzymes such as the CYPs, was postulated as one reason for their failure.

Synthesis and in vivo anticancer and antiangiogenic effects of novel thioxothiazolidin-4-one derivatives against transplantable mouse tumor

A series of novel thioxothiazolidin-4-one derivatives 5(a-g) were synthesized by the coupling of different amines containing aliphatic, substituted aromatic, and heterocyclic moieties, such as oxadiazol, pyrazole, isoxazole, and piperazine with 2-(5-(4-chlorophenyl)furan-2-yl)methylene)-4-oxo- 2-thioxothiazolidin-3-yl)acetic acid. All compounds were characterized by 1H NMR, LCMS, FTIR and elemental analysis. In this study, we investigated the possibility that these novel thioxothiazolidin-4-one derivatives 5(a-g) inhibits tumor growth and tumor induced angiogenesis using mouse Ehrlich Ascites Tumor (EAT) as a model system. Our results demonstrated that the compounds significantly reduced ascites tumor volume, cell number, and increased the life span of EAT-bearing mice. In addition, the compounds manifested strong antiangiogenic effects and suppressed tumor induced endothelial proliferation in the mice peritoneum. From our findings, it is noted that the derivatives 5(a-e) may be possible candidates for anticancer therapy with the ability to inhibit tumor angiogenesis and tumor cell proliferation.

Synthesis of some unusual (1,2,4-oxadiazole)-linked hexenopyranosides and mannopyranosides

A copper-catalyzed reaction of propargyl 4,6-di-O-acetyl-2,3-dideoxy- α-D-erythro-hex-2-enopyranoside with 3-(4-azidophenyl)-1,2,4-oxadiazoles gave the corresponding hexenopyranosides bearing an 1,2,4-oxadiazole subunit in the aglyconic part of the molecu

Muscarinic acetylcholine receptor antagonists: SAR and optimization of tyrosine ureas

SAR exploration of multiple regions of a tyrosine urea template led to the identification of very potent muscarinic acetylcholine receptor antagonists such as 10b with good subtype selectivity for M3 over M1. The structure-activity r

CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS

Chroman derivatives according to Formula (I) below: wherein R1, R2, R3 ,and R4 are as defined in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical .compositions containing a

HYDRAZONE DERIVATIVE

A compound represented by the following formula (I): wherein R1 represents hydrogen, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc.; R2 represents hydrogen, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc.; R3 represents hydrogen, etc.; Ar represents a divalent group derived from aromatic hydrocarbon, etc.; X represents a single bond, linear or branched alkylene having from 1 to 3 carbon atoms which may have a substituent, etc.; and G represents halogen, a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc., a salt thereof or a solvate thereof; and an agent for inhibiting aggregation and/or deposition of an amyloid protein or an amyloid-like protein, which comprises the compound, a salt thereof or a solvate thereof

Environmentally friendly and efficient: Iron-mediated reduction of 3-methyl-5-aryl-1,2,4-oxadiazoles to benzamidines

A new synthetic method is described for the mild and selective reduction of 3-methyl-5-aryl-1,2,4-oxadiazoles to amidines employing iron powder in aqueous medium. Its application is demonstrated in the synthesis of 1, a potent and selective urokinase-type plasminogen activator (uPA) inhibitor.